


80. (Amended) A pharmaceutical composition, comprising an agent selected from a ubiquinone, or pharmaceutically or veterinarily acceptable salt thereof, wherein the ubiquinone has the chemical formula



(CoQ<sub>n</sub>);

wherein n=1 to 12;

the active agent is present in an amount effective for altering levels of, or sensitivity to, adenosine in a subject's tissue (s), or treating bronchoconstriction, lung inflammation or allergy(ies), chronic obstructive pulmonary disease (COPD) or a disease associated with either of them.

B2

86. (Amended) The composition of claim 159, wherein the compound of formula (I) is dehydroepiandrosterone, wherein R and R' are each hydrogen and the broken line represents a double bond.

87. (Amended) The composition of claim 159, wherein the compound of formula (I) is 16-alpha bromoepiandrosterone, wherein R is Br, R<sup>1</sup> is H, and the broken line represents a double bond.

88. (Amended) The composition of claim 159, wherein the compound of formula (I) is 16-alpha-fluoro epiandrosterone, wherein R is F, R<sup>1</sup> is H and the broken line represents a double bond.

89. (Amended) The composition of claim 159, wherein the compound of formula (I) is etiocholanolone, wherein R and R<sup>1</sup> are each hydrogen and the broken line represents a double bond.

90. (Amended) The composition of claim 159, wherein the compound of formula

(I) is dehydroepiandrosterone sulfate, wherein R is H, R<sup>1</sup> is SO<sub>2</sub>OM and M is a sulfatide group as defined above, and the broken line represents a single bond.

B2  
cont

91. (Amended) The composition of claim 159, wherein in the compound of formula (1), R is halogen selected from Br, Cl or F, R<sup>1</sup> is H, and the broken line represents a double bond.

92. (Amended) The composition of claim 159, wherein the compound of formula (I) is 16-alpha-fluoro epiandrosterone.

93. (Amended) The composition of claim 159, wherein the compound of formula (I) is selected from dehydroepiandrosterone, 16-alpha-bromoepiandrosterone, 16-alpha-fluoro epiandrosterone, etiocholanolone, dehydroepiandrosterone sulfate or pharmaceutically or veterinarily acceptable salts thereof.

B3

97. (Amended) A formulation comprising the composition of claim 94, wherein the formulation is a systemic or topical formulation.

B4

116. (Amended) The formulation of claim 115, comprising an inhalable or respirable formulation comprising powdered or liquid particles of the active agent about 0.05  $\mu$ m to about 10  $\mu$ m in size.

117. (Amended) The formulation of claim 116, comprising an inhalable or respirable aerosol formulation comprising powdered or liquid particles of the active agent about 0.1  $\mu$ m to about 5  $\mu$ m in size.

118. (Amended) The formulation of claim 115, which comprises a nasal or intrapulmonary aerosol formulation comprising powdered or liquid particles of the active agent about 10  $\mu$ m to about 100  $\mu$ m in size.

119. (Amended) The formulation of claim 118, which comprises powdered or liquid particles of the active agent about 10  $\mu$ m to about 50  $\mu$ m in size.

B5

127. (Amended) The kit of claim 121, wherein the formulation is provided in a

BS  
cont


pierceable or openable capsule or cartridge.

Please cancel Claims 128-156.

Please add the following new claim:

136

159. (New) The pharmaceutical composition of claim 80, further comprising a dehydroepiandrosterone (DHEA), a pharmaceutically or veterinarily acceptable salts thereof, or a mixture thereof, the dehydroepiandrosterone having the chemical formula



(DHEA) (I)

wherein the broken line represents a single or a double bond; R is hydrogen or a halogen; the H at position 5 is present in the alpha or beta configuration or the compound of chemical formula I comprises a racemic mixture of both configurations; and R1 is hydrogen or SO<sub>2</sub>OM, wherein M is selected from the group consisting of H, Na, sulfatide -SO<sub>2</sub>O-CH<sub>2</sub>CHCH<sub>2</sub>OCOR<sup>3</sup>; and phosphatide



O

||

-P-OCH<sub>2</sub>CHCH<sub>2</sub>OCOR<sup>3</sup>, wherein R<sup>2</sup> and R<sup>3</sup>, which may be the same or different, are straight or

||

|

O

OCOR<sup>2</sup>


branched (C<sub>1</sub>-C<sub>14</sub>) alkyl or glucuronide,

Clean Version of Replacement Claims

In the Claims

Claims 80, 86-93, 97 and 116-119 are amended as follows:

80. (Amended) A pharmaceutical composition, comprising an agent selected from a ubiquinone, or pharmaceutically or veterinarily acceptable salt thereof, wherein the ubiquinone has the chemical formula



wherein n=1 to 12;

the active agent is present in an amount effective for altering levels of, or sensitivity to, adenosine in a subject's tissue (s), or treating bronchoconstriction, lung inflammation or allergy(ies), chronic obstructive pulmonary disease (COPD) or a disease associated with either of them.

86. (Amended) The composition of claim 159, wherein the compound of formula (I) is dehydroepiandrosterone, wherein R and R' are each hydrogen and the broken line represents a double bond.

87. (Amended) The composition of claim 159, wherein the compound of formula (I) is 16-alpha bromoepiandrosterone, wherein R is Br, R<sup>1</sup> is H, and the broken line represents a double bond.

88. (Amended) The composition of claim 159, wherein the compound of formula (I) is 16-alpha-fluoro epiandrosterone, wherein R is F, R<sup>1</sup> is H and the broken line represents a double bond.

89. (Amended) The composition of claim 159, wherein the compound of formula

(I) is etiocholanolone, wherein R and R<sup>1</sup> are each hydrogen and the broken line represents a double bond.

90. (Amended) The composition of claim 159, wherein the compound of formula (I) is dehydroepiandrosterone sulfate, wherein R is H, R<sup>1</sup> is SO<sub>2</sub>OM and M is a sulfatide group as defined above, and the broken line represents a single bond.

91. (Amended) The composition of claim 159, wherein in the compound of formula (1), R is halogen selected from Br, Cl or F, R<sup>1</sup> is H, and the broken line represents a double bond.

92. (Amended) The composition of claim 159, wherein the compound of formula (I) is 16-alpha-fluoro epiandrosterone.

93. (Amended) The composition of claim 159, wherein the compound of formula (I) is selected from dehydroepiandrosterone, 16-alpha-bromoepiandrosterone, 16-alpha-fluoro epiandrosterone, etiocholanolone, dehydroepiandrosterone sulfate or pharmaceutically or veterinarily acceptable salts thereof.

97. (Amended) A formulation comprising the composition of claim 94, wherein the formulation is a systemic or topical formulation.

116. (Amended) The formulation of claim 115, comprising an inhalable or respirable formulation comprising powdered or liquid particles of the active agent about 0.05 μm to about 10 μm in size.

117. (Amended) The formulation of claim 116, comprising an inhalable or respirable aerosol formulation comprising powdered or liquid particles of the active agent about 0.1 μm to about 5 μm in size.

118. (Amended) The formulation of claim 115, which comprises a nasal or intrapulmonary aerosol formulation comprising powdered or liquid particles of the active agent about 10 μm to about 100 μm in size.


119. (Amended) The formulation of claim 118, which comprises powdered or liquid particles of the active agent about 10  $\mu\text{m}$  to about 50  $\mu\text{m}$  in size.

127. (Amended) The kit of claim 121, wherein the formulation is provided in a pierceable or openable capsule or cartridge.


Please cancel Claims 128-156.

Please add the following new claim:

159. (New) The pharmaceutical composition of claim 80, further comprising a dehydroepiandrosterone (DHEA), a pharmaceutically or veterinarily acceptable salts thereof, or a mixture thereof, the dehydroepiandrosterone having the chemical formula



wherein the broken line represents a single or a double bond; R is hydrogen or a halogen; the H at position 5 is present in the alpha or beta configuration or the compound of chemical formula I comprises a racemic mixture of both configurations; and R1 is hydrogen or  $\text{SO}_2\text{OM}$ , wherein M is selected from the group consisting of H, Na, sulfatide  $-\text{SO}_2\text{O}-\text{CH}_2\text{CHCH}_2\text{OCOR}^3$ ; and phosphatide



O

||


$-\text{P}-\text{OCH}_2\text{CHCH}_2\text{OCOR}^3$ , wherein  $\text{R}^2$  and  $\text{R}^3$ , which may be the same or different, are straight or

||

O

OCOR<sup>2</sup>

branched (C<sub>1</sub>-C<sub>14</sub>) alkyl or glucuronide,



3,4-Dihydroxy-3,5,6-trimethyl-tetrahydro-pyran-2-carboxylic acid

; wherein the DHEA, or pharmaceutically or veterinarily acceptable salts thereof, is present in an amount effective for altering levels of, or sensitivity to, adenosine in a subject's tissue (s), or treating bronchoconstriction, lung inflammation or allergy(ies), COPD or a disease associated with either of them.